Back

Leios licenses 10XB-101 to CMS, expects China trial to start in early 2027

Verifying
  • Leios granted CMS exclusive China rights for 10XB-101 development, manufacturing and commercialization.
  • 64% and 70% of higher-dose study completers achieved at least grade 2 improvement versus 0% placebo.
  • Leios expects to begin the China trial in early 2027 after partnering with BNC Korea.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.